Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 3;10(9):864.
doi: 10.3390/biology10090864.

Next Generation Sequencing Technology in Lung Cancer Diagnosis

Calin Cainap  1   2 , Ovidiu Balacescu  3 , Simona Sorana Cainap  4   5 , Laura-Ancuta Pop  6
Affiliations
Review

Next Generation Sequencing Technology in Lung Cancer Diagnosis

Calin Cainap et al. Biology (Basel). .

Abstract

Lung cancer is still one of the most commonly diagnosed cancers, and one of the deadliest. The high death rate is mainly due to the late stage of diagnosis and low response rate to therapy. Previous and ongoing research studies have tried to discover new reliable and useful cbiomarkers for the diagnosis and prognosis of lung cancer. Next generation sequencing has become an essential tool in cancer diagnosis, prognosis, and evaluation of the treatment response. This article aims to review the leading research and clinical applications in lung cancer diagnosis using next generation sequencing. In this scope, we identified the most relevant articles that present the successful use of next generation sequencing in identifying biomarkers for early diagnosis correlated to lung cancer diagnosis and treatment. This technique can be used to evaluate a high number of biomarkers in a short period of time and from small biological samples, which makes NGS the preferred technique to develop clinical tests for personalized medicine using liquid biopsy, the new trend in oncology.

Keywords: diagnosis; lung cancer; next generation sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. System E.-E.C.I. Lung cancer incidance and mortality 2020. 2021. [(accessed on 26 July 2021)]. Available online: https://ecis.jrc.ec.europa.eu.
    1. Mao Y., Yang D., He J., Krasna M.J. Epidemiology of Lung Cancer. Surg. Oncol. Clin. N. Am. 2016;25:439–445. doi: 10.1016/j.soc.2016.02.001. - DOI - PubMed
    1. Travis W.D., Brambilla E., Burke A.P., Marx A., Nicholson A.G. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer. 2015;10:1240–1242. doi: 10.1097/JTO.0000000000000663. - DOI - PubMed
    1. Wood D.E., Kazerooni E.A., Baum S.L., Eapen G.A., Ettinger D.S., Hou L., Jackman D.M., Klippenstein D., Kumar R., Lackner R.P., et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN. 2018;16:412–441. doi: 10.6004/jnccn.2018.0020. - DOI - PMC - PubMed
    1. Becker N., Motsch E., Trotter A., Heussel C.P., Dienemann H., Schnabel P.A., Kauczor H.U., Maldonado S.G., Miller A.B., Kaaks R., et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int. J. Cancer. 2020;146:1503–1513. doi: 10.1002/ijc.32486. - DOI - PubMed

LinkOut - more resources